No Products in the Cart
Obesity is a common, serious, multifactorial disease. Obesity-related conditions include heart disease, stroke, type 2 diabetes and certain types of cancer. These are among the leading causes of preventable, premature death. But, as time goes on, and our understanding of obesity and metabolic health advances, we are learning that obesity and weight loss are far more complex, nuanced, and multifactorial than previously thought. Losing weight is not as simple as “eat less, exercise more.” Many individuals have tried numerous dietary and exercise interventions to lose weight, only to be met with incredible frustration, as weight loss continues to be difficult for them to achieve and maintain.
"There is no one size fits all for nutrition, diet, exercise, and weight loss.
So, what is semaglutide? First: a once-weekly subcutaneous injection of semaglutide 1.0 mg called Ozempic, a GLP-1, was approved for the treatment of type 2 diabetes, and has proven to reduce the risk of cardiovascular events in people with type 2 diabetes and cardiovascular disease.
Then following this, the groundbreaking STEP 1 Trial, demonstrated that a higher dose of semaglutide, 2.4 mg (now known as Wegovy) could result in unbelievable weight loss and improvements in cardiometabolic health! They significantly decreased their waist circumference, their blood pressure, inflammatory markers, blood sugar markers such as HgbA1c, fasting plasma glucose, and serum insulin, and their triglycerides!
The individuals on semaglutide had almost 15% weight loss in 68 weeks, compared to just 2.4% weight loss in the placebo group!
A 104-week trial investigated the long-term effect of semaglutide 2.4mg compared with placebo on body weight and cardiometabolic risk factors in adults with overweight or obesity in adults over 18 years old without type 2 diabetes.
At 2 years, individuals who were adherent taking their semaglutide 2.4mg once weekly (wegovy) lost 16.7% of their body weight, and sustained this weight loss!
At 2 years, 83.3% individuals who were adherent taking their semaglutide 2.4mg once weekly (Wegovy) maintained greater than 5% weight loss.
They found that 56.8% of individuals maintained GREATER than 15% weight loss, and almost 40% of individuals maintained greater than 20% weight loss!
In June 2021, this groundbreaking medication Wegovy was approved by the FDA for weight management in adults with obesity or overweight with ≥1 weight-related comorbidity (such as hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease.)
Let’s be clear: no FDA approved weight loss medication, no diet or exercise program, to date, has ever demonstrated this result. Outside of bariatric surgery, this is the most effective weight loss intervention to date!
If you have been struggling with weight loss, have tried numerous diet and exercise programs, only to feel frustrated and stuck at the same weight, it may be time to consider talking to our team about medical therapy.